Alcon(US:ALC) ZACKS·2026-02-25 04:30Core Insights - Alcon reported $2.7 billion in revenue for Q4 2025, marking a year-over-year increase of 9.1% and an EPS of $0.78, up from $0.72 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate by 0.2%, while the EPS also missed the consensus estimate by 0.76% [1] Financial Performance Metrics - Total Surgical Equipment/Other net sales were $277 million, a 21% increase year-over-year, but slightly below the average estimate of $277.54 million [4] - Total Surgical Implantables net sales reached $474 million, reflecting a 4% year-over-year increase, but below the estimated $482.1 million [4] - Total Surgical net sales amounted to $1.55 billion, an 8.6% year-over-year increase, slightly under the average estimate of $1.56 billion [4] - Total Vision Care net sales were $1.16 billion, a 9.8% increase year-over-year, exceeding the average estimate of $1.15 billion [4] - Total Surgical Consumables net sales were $794 million, a 7.6% year-over-year increase, just below the average estimate of $796.13 million [4] - Total Vision Care Contact Lenses net sales were $683 million, a 7.1% increase year-over-year, slightly below the average estimate of $687.14 million [4] - Total Vision Care Ocular Health net sales reached $474 million, a 13.9% year-over-year increase, surpassing the average estimate of $462.7 million [4] - Other revenues were reported at $16 million, a significant decline of 36% year-over-year, and below the estimated $26.18 million [4] - Overall net sales matched the average estimate of $2.7 billion [4] Stock Performance - Alcon shares have returned +2.6% over the past month, outperforming the Zacks S&P 500 composite, which saw a -1% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]